Human Optic Neuritis Prevalence and Characteristics

The annual prevalence of optic neuritis (ON) among commercial insurance enrollees was stable from 2016 (39.46 per 100,000) to 2024 (41.32 per 100,000). Females, those aged 41-64, and residents in the Northeast and North Central regions had higher prevalence. Between 36.32%-42.11% of ON patients also had multiple sclerosis, yet corticosteroid treatment rates post-ON visits were low (2.93%-4.62%).

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42779082)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This stability in ON prevalence among commercially insured adults may suggest consistent patterns in the incidence of this condition over time, but the findings highlight disparities in how ON affects different demographics. The low rate of corticosteroid treatments post-diagnosis raises concerns about treatment utilization.

What this does not prove

This study is limited to commercially insured adults, making results less applicable to the broader population. It does not establish cause-and-effect relationships or evaluate treatment efficacy for ON.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: Not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-09-23
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidencePrevalence of Optic Neuritis and Corticosteroid Use in Adults in the United States, 2016-2024. ↗DOI: 10.1080/09286586.2026.2734831

Supporting passages (5)

study designThis study analyzed 2016-2024 Merative MarketScan Commercial healthcare claims data.

subjectsThis study aimed to examine the prevalence of ON, sociodemographic characteristics, and corticosteroid use among adult ON patients in the US.

findingsThe annual prevalence of ON among commercial insurance enrollees remained stable from 39.46 per 100,000 enrollees in 2016 to 41.32 per 100,000 in 2024.

limitationsCONCLUSION: In this population-based study, the prevalence of ON remained stable over time among commercially insured US adults, with consistent differences observed by sex, age, and geographic region.

publication datePublication date: 2026-09-23

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.